Drugs / MK3207
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00548353 | Aug 2007 → Apr 2008 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00712725 | Jul 2008 → Jan 2009 | migraine disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3207 | “BACKGROUND: This study evaluated the CGRP receptor antagonist MK-3207 for acute treatment of migraine.” PMID 21383045 ↗ Mar 2011 |
| Known as | M3207 | “M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).” NCT00548353 ↗ |
| Action | Inhibit | “BACKGROUND: This study evaluated the CGRP receptor antagonist MK-3207 for acute treatment of migraine.” PMID 21383045 ↗ Mar 20111“Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL1910936 ↗ |
| Modality | Small molecule | — CHEMBL1910936 ↗ |
| Route | Oral | “MK3207 Orally administered to patients with water.” NCT00548353 ↗ |
| Target | CALCRL | “Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL1910936 ↗ |